Treating Adenovirus Infection in Transplant Populations: Therapeutic Options Beyond Cidofovir?

Area of Science:

• Virology
• Immunology
• Pharmacology

Background:

• Adenovirus (AdV) infections cause significant illness and death in immunocompromised patients, particularly transplant recipients.
• Current treatments like cidofovir have limitations including variable effectiveness and toxicity.
• Existing antiviral drugs (ribavirin, ganciclovir) show inconsistent efficacy against AdV.

Purpose of the Study:

• To review and evaluate existing and emerging therapies for adenovirus infections.
• To identify challenges and unmet needs in AdV management for immunocompromised populations.
• To highlight the need for improved treatment strategies and further research.

Main Methods:

• Systematic review of current and emerging AdV therapies.
• Analysis of clinical data on antiviral drugs and immune-based approaches.
• Evaluation of safety profiles and efficacy of different treatment modalities.

Main Results:

• Brincidofovir shows promise with a better safety profile and in vitro potency compared to cidofovir.
• Adoptive T-cell therapy demonstrates potential for viral clearance but faces manufacturing and safety hurdles.
• Existing therapies like ribavirin and ganciclovir have limited efficacy.

Conclusions:

• There is a critical need for standardized treatment protocols and comparative studies for AdV infections.
• Individualized treatment approaches and novel therapeutic agents are essential for effective AdV management.
• Further research is required to address the unmet clinical needs in adenovirus management.